NASDAQ:CUE - Cue Biopharma, Inc.
$7.14
 $-0.41
-5.43%
4:00PM EDT
2019-07-22
Cue Biopharma Inc, incorporated on December 31, 2014, is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.Immuno-Oncology CUE-100 FrameworkThe CUE-100 Framework restricts the activity of T cell populations. The lead component of CUE-100 Framework is CUE-101 a fusion variant of cytokine Interleukin-2. It treats the unmet clinical needs like human papilloma virus driven cancers. Immuno-Oncology CUE-200 FrameworkThe CUE-200 Framework is designed to enable potent, long-lived T cell responses against the tumor cells that evade the immune system. It aims at stimulating and activating the naive T cells for anti-tumor responsesAutoimmune DiseaseThe Autoimmune disease therapy protects the healthy cells from immune attack by modulating the immune system. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CUE     avg for
industry  
  avg for
sector  
42 stocks weight:  17. 92   0. 00   0. 00  
42 stocks rank:  3. 44 K 1. 35 K 799. 74  
# analyst opinions:  1. 00   12. 76   13. 14  

quick ratio:  2. 92   5. 61   1. 85  
current ratio:  3. 02   6. 00   2. 31  

target price low:  14. 50   75. 88   108. 31  
target price avg:  14. 50   97. 27   130. 10  
target price high:  14. 50   124. 58   149. 02  
1-yr high:  11. 86   104. 89   135. 09  
last close:  7. 14   79. 79   118. 76  
50-day avg:  7. 92   79. 39   116. 18  
200-day avg:  6. 93   81. 61   114. 52  
1-yr low:  4. 35   62. 76   94. 70  
volume:  339. 15 K 2. 99 M 4. 43 M
50-day avg volume:  91. 80 K 3. 39 M 4. 22 M
200-day avg volume:  96. 51 K 3. 13 M 4. 83 M

1-day return:  -5. 43 % 0. 33 % 0. 14 %
this week return:  -5. 43 % 0. 33 % 0. 14 %
12-wk return:  -11. 19 % 1. 00 % 3. 51 %
52-wk return:  -35. 62 % 0. 58 % 10. 25 %

enterprise value (EV):  134. 63 M 44. 78 B 115. 63 B
market cap:  148. 39 M 38. 01 B 103. 29 B
EBITDA:  -41. 80 M 4. 47 B 7. 73 B
enterprise multiple (EV/EBITDA):  -3. 22   2. 11   11. 26  
enterprise/revenue (EV/R):  89. 00   61. 53   10. 40  
total revenue:  1. 51 M 10. 43 B 31. 15 B
total debt:  8. 59 M 11. 72 B 16. 76 B
debt/equity:  34. 73   61. 22   124. 43  
net income (common):  -42. 72 M 2. 06 B 3. 79 B

shares outstanding:  20. 78 M 562. 08 M 1. 27 B
shares:  16. 32 M 573. 33 M 1. 26 B
shares short:  1. 23 M 11. 60 M 12. 29 M
shares short prior month:  1. 26 M 9. 81 M 12. 46 M
short ratio:  13. 77   5. 88   3. 41  
short % of float:  6. 49 % 6. 88 % 2. 72 %
total cash/share:  1. 49   10. 62   8. 83  
total cash:  30. 88 M 6. 17 B 5. 72 B
free cash flow:  -14. 17 M 3. 08 B 3. 10 B
operating cash flow:  -25. 13 M 3. 99 B 4. 08 B

book value:  1. 19   12. 74   26. 25  
price/book:  6. 00   4. 38   9. 01  
gross profits:  -24. 56 M 7. 93 B 35. 64 B
operating margins:  -2816. 45 % -319. 65 % -29. 05 %
EBITDA margins:  0. 00 % 11. 82 % 24. 13 %
profit margins:  0. 00 % 5. 62 % 14. 29 %
gross margins:  0. 00 % 34. 75 % 57. 07 %

1-yr max volatility:  16. 13 % --- ---
1-yr mean volatility:  3. 66 % 1. 95 % 1. 25 %

1-yr EPS:  -2. 10   1. 58   3. 82  
forward EPS:  -1. 79   3. 16   6. 65  
P/E:  -3. 39   0. 21   31. 97  
forward P/E:  -4. 22   4. 95   15. 14  
PE/G:  0. 18   0. 74   0. 13  
growth:  -18. 80 % 295. 81 % 85. 47 %
earnings high:  -0. 00   0. 84   1. 56  
earnings avg:  -0. 00   0. 65   1. 45  
earnings low:  -0. 00   0. 40   1. 35  
revenue high:  220. 00 K 2. 70 B 8. 76 B
revenue avg:  220. 00 K 2. 64 B 8. 62 B
revenue low:  220. 00 K 2. 58 B 8. 45 B
return on assets:  -50. 95 % -3. 43 % 4. 51 %
return on equity:  -106. 84 % -104. 30 % 140. 44 %
revenue/share:  0. 07   12. 50   51. 58  

beta (1yr vs S&P500):  0. 68   1. 27   0. 91  
sharpe (1yr):  -0. 21   0. 20   0. 80  

held % insiders:  19. 24 % 6. 63 % 3. 46 %
held % institutions:  20. 69 % 76. 45 % 67. 87 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-22 : CUE
.    106.988 =       106.988 :: --> INITIAL WEIGHT <--
.    - 2.105 =       104.883 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.953 =       309.727 :: P/E factor
.    x 1.534 =        475.21 :: PE/G factor
.    x 1.491 =       708.599 :: beta factor
.    x 0.712 =       504.601 :: sharpe factor
.    x 2.504 =      1263.427 :: current ratio factor
.    x 1.233 =      1557.946 :: quick ratio factor
.    x 1.036 =      1613.525 :: short ratio factor
.    x 1.554 =      2506.701 :: EV/R factor
.    x 1.073 =      2689.242 :: price-to-book factor
.    x 0.701 =      1884.082 :: debt-to-revenue factor
.    x 1.252 =      2358.677 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.759 =      6508.145 :: sector+industry 1-year gains factor
.     x 1.01 =      6573.129 :: industry 12-weeks return factor
.    x 1.309 =      8606.635 :: industry 2-weeks return factor
.    x 1.106 =      9515.733 :: 5-day avg > 200-day avg
.    x 1.142 =     10865.279 :: 50-day avg > 200-day avg
.    x 0.967 =      10502.88 :: "drift" penalty 5 days ago
.    / 2.112 =      4972.843 :: overall "drift" factor
.    x 0.694 =      3452.057 :: largest single-day jump factor
.      x 0.1 =        343.83 :: low price factor
.    x 1.537 =       528.505 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.831 =         439.1 :: forward EPS factor
.    x 0.939 =       412.108 :: forward P/E factor
.    x 1.184 =       487.919 :: industry recommendation factor
.    x 1.002 =       488.661 :: factor historical industry gain for week 29
.     x 5.28 =      2580.342 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         7.127 :: reduced for readability
.   + 10.792 =        17.919 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     17.919 :: FINAL WEIGHT for NASDAQ:CUE


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org